DEPOSIT AGREEMENT by and among INNATE PHARMA S.A. and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of [date], [year]Deposit Agreement • October 4th, 2019 • Innate Pharma SA • Biological products, (no disgnostic substances) • Delaware
DEPOSIT AGREEMENT, dated as of ___________, 20__, by and among (i) INNATE PHARMA S.A., a company organized under the laws of France, and its successors (the “Company”), (ii) CITIBANK, N.A., a national banking association organized under the laws of the United States of America (“Citibank”) acting in its capacity as depositary, and any successor depositary hereunder (Citibank in such capacity, the “Depositary”), and (iii) all Holders and Beneficial Owners of American Depositary Shares issued hereunder (all such capitalized terms as hereinafter defined).
●] American Depositary Shares Representing [●] Ordinary Shares (Par Value €0.05 Per Share) INNATE PHARMA S.A. UNDERWRITING AGREEMENTUnderwriting Agreement • October 4th, 2019 • Innate Pharma SA • Biological products, (no disgnostic substances) • New York
This letter is being delivered to you in connection with the offering by Innate Pharma S.A. (the “Company”) of (i) ordinary shares, par value €0.05 per share (the “Ordinary Shares”) and (ii) Ordinary Shares to be delivered in the form of American Depositary Shares (“ADSs”), of the Company and the lock-up letter dated ____, 2019 (the “Lock-Up Letter”), executed by you in connection with such offering, and your request for a [waiver] [release] dated ____, 2019, with respect to [____ Ordinary Shares (the “Lock-Up Shares”)] [____ ADSs (the “Lock-Up ADSs”)].
